NexTechie BioFlux - The Brief: Telehealth Cliff, EU Regulation, Novel Drug Delivery Scrutiny Analysed

This BioFlux edition explores critical shifts in health tech, biotech, and medtech. We analyze the impending "telehealth cliff" as Medicare's pandemic flexibilities expire, impacting U.S. patient access and provider operations, alongside legislative uncertainty. In Europe, the EU's ambitious regulatory overhaul, including the FAST-EU initiative and proposed Biotech Act, aims to significantly accelerate clinical trial authorizations and reshape the competitive landscape. Additionally, we scrutinize the FDA's review of Aquestive's novel oral epinephrine film, Anaphylm, highlighting challenges for innovative drug delivery technologies. This issue offers essential intelligence to navigate these pivotal policy, regulatory, and technological transformations.Subscribe to the paid version of NexTechie BioFlux Newsletter on Patreon to gain full access to a Detailed Video and the full Newsletter. NexTechie Premium: https://www.patreon.com/nextechie Statutory Declaration: Artificial Intelligence has been utilized within the editorial workflow and in the production of audio and video content, under strict human oversight and comprehensive editorial guidance.